Analysts predict that Neurocrine Biosciences, Inc. (NASDAQ:NBIX) will post sales of $24.60 million for the current quarter, according to Zacks. Seven analysts have issued estimates for Neurocrine Biosciences’ earnings. The highest sales estimate is $31.64 million and the lowest is $19.00 million. The firm is expected to report its next earnings report on Wednesday, November 1st.

On average, analysts expect that Neurocrine Biosciences will report full-year sales of $24.60 million for the current fiscal year, with estimates ranging from $42.10 million to $81.12 million. For the next year, analysts anticipate that the company will post sales of $163.37 million per share, with estimates ranging from $108.00 million to $203.53 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of sell-side research analysts that follow Neurocrine Biosciences.

Neurocrine Biosciences (NASDAQ:NBIX) last announced its quarterly earnings results on Thursday, August 3rd. The company reported ($0.68) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.67) by $0.01. The business had revenue of $6.34 million during the quarter, compared to analysts’ expectations of $0.61 million. During the same quarter last year, the business earned ($0.46) EPS.

NBIX has been the topic of a number of recent research reports. Robert W. Baird restated an “outperform” rating and set a $66.00 price objective on shares of Neurocrine Biosciences in a research note on Friday, April 14th. Piper Jaffray Companies restated an “overweight” rating and set a $80.00 price objective on shares of Neurocrine Biosciences in a research note on Monday, April 17th. BMO Capital Markets restated an “outperform” rating and set a $72.00 price objective on shares of Neurocrine Biosciences in a research note on Monday, April 17th. Needham & Company LLC restated a “buy” rating and set a $62.00 price objective on shares of Neurocrine Biosciences in a research note on Monday, April 17th. Finally, Jefferies Group LLC raised their price objective on Neurocrine Biosciences from $65.00 to $67.00 and gave the stock a “buy” rating in a research note on Monday, May 1st. One investment analyst has rated the stock with a sell rating, one has given a hold rating and seventeen have assigned a buy rating to the stock. The company has an average rating of “Buy” and a consensus price target of $68.25.

TRADEMARK VIOLATION WARNING: “Neurocrine Biosciences, Inc. (NBIX) Expected to Announce Quarterly Sales of $24.60 Million” was first posted by Daily Political and is owned by of Daily Political. If you are reading this piece on another domain, it was stolen and reposted in violation of U.S. and international trademark and copyright law. The original version of this piece can be read at https://www.dailypolitical.com/2017/08/11/neurocrine-biosciences-inc-nbix-expected-to-announce-quarterly-sales-of-24-60-million.html.

Shares of Neurocrine Biosciences (NASDAQ:NBIX) opened at 53.85 on Friday. Neurocrine Biosciences has a 12 month low of $37.35 and a 12 month high of $55.38. The firm has a 50-day moving average price of $48.33 and a 200-day moving average price of $46.68. The company’s market capitalization is $4.75 billion.

In related news, insider Dimitri E. Grigoriadis sold 10,000 shares of the business’s stock in a transaction on Tuesday, May 23rd. The stock was sold at an average price of $53.39, for a total transaction of $533,900.00. Following the sale, the insider now owns 107,691 shares in the company, valued at approximately $5,749,622.49. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Christopher Flint Obrien sold 8,734 shares of the business’s stock in a transaction on Thursday, July 27th. The stock was sold at an average price of $50.00, for a total value of $436,700.00. Following the sale, the insider now owns 57,707 shares in the company, valued at approximately $2,885,350. The disclosure for this sale can be found here. Insiders have sold a total of 51,194 shares of company stock worth $2,629,755 in the last 90 days. 4.80% of the stock is currently owned by corporate insiders.

A number of large investors have recently modified their holdings of NBIX. Independent Portfolio Consultants Inc. purchased a new stake in shares of Neurocrine Biosciences during the first quarter worth $106,000. First Mercantile Trust Co. raised its stake in shares of Neurocrine Biosciences by 22.2% in the first quarter. First Mercantile Trust Co. now owns 3,082 shares of the company’s stock worth $133,000 after buying an additional 560 shares in the last quarter. ARS Investment Partners LLC purchased a new stake in shares of Neurocrine Biosciences during the second quarter worth $207,000. Stephens Inc. AR purchased a new stake in shares of Neurocrine Biosciences during the second quarter worth $207,000. Finally, Capstone Asset Management Co. purchased a new stake in shares of Neurocrine Biosciences during the first quarter worth $214,000. Institutional investors and hedge funds own 96.48% of the company’s stock.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development (R&D) platform, focused on neurological and endocrine based diseases and disorders. Its three lead late-stage clinical programs are elagolix, which is a gonadotropin-releasing hormone (GnRH) antagonist for endometriosis and uterine fibroids; INGREZZA (valbenazine), which is a vesicular monoamine transporter 2 (VMAT2) inhibitor, for the treatment of movement disorders, and opicapone, which is a selective catechol-O-methyltransferase inhibitor that is an adjunct therapy to preparations of levodopa/Dihydroxyphenylalanine (DOPA) decarboxylase inhibitors for adult patients with Parkinson’s disease.

Get a free copy of the Zacks research report on Neurocrine Biosciences (NBIX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Neurocrine Biosciences (NASDAQ:NBIX)

Receive News & Ratings for Neurocrine Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.